Using electronic cigarettes, or vaping, has become increasingly popular within the past several years. Within the past few months, an outbreak of vaping-associated pulmonary injury (VAPI) has been recognized in locations across the United States. The number of patients involved has rapidly increased to the hundreds, and several deaths have been reported.
This is currently an area of active investigation about which little is known for certain.
Here’s what we do know.
Quick Tips: Diagnosis and Treatment
Available evidence suggests that the predominant form of lung injury is lipoid pneumonia. This may relate largely to the vaping of tetrahydrocannabinol (marijuana-like) products, which are diluted using vitamin E acetate. However, not all patients report a history of vaping with tetrahydrocannabinol, so other products may be involved as well.
The clinical presentation of VAPI usually begins gradually over several days with gastrointestinal and pulmonary symptoms. Early on, patients may appear to have a viral gastroenteritis or mild pneumonia. Eventually hypoxemic respiratory compromise worsens, with the development of bilateral pulmonary infiltrates. Additional symptoms may include fever, chest pain, and weight loss. CT scans typically show bilateral diffuse ground-glass opacification. Steroid administration may be associated with clinical improvement, although this remains unproven and speculative. Severity is variable, with some patients requiring intubation or even extracorporeal membrane oxygenation.
The optimal approach to investigation and treatment of this disorder remains unknown. Evaluation is primarily driven toward exclusion of alternative likely possibilities (especially various types of infectious pneumonia). Whether every patient requires a bronchoscopy is debatable. For critically ill patients at risk of deterioration, the safest approach could be to provide empiric therapy for both pneumonia and VAPI (current approaches are a combination of antibiotics and a steroid).
This is a rapidly evolving topic, and approaches are likely to evolve even as this goes to print. The most important aspect is to be aware that VAPI exists. This awareness should prompt us to take a detailed vaping history among patients with respiratory or gastrointestinal symptoms, especially in otherwise healthy patients not expected to develop acute respiratory illnesses. In suspected cases, specialty consultation may be advisable (most often pulmonology), and local health departments should be notified as they can provide updated clinical guidance and assist in tracking cases.
The Devil We Don’t Know
Vaping’s popularity has been, in part, driven by the medical community, which has viewed the habit as a safer alternative to smoking cigarettes. Unfortunately, the use of vaping as a smoking cessation strategy is scientifically a bit dodgy. Our understanding of the toxicity of cigarettes emerged very slowly. This toxicity wasn’t recognized for decades, until long-term epidemiological evidence implicated smoking in lung cancer. Since vaping hasn’t been around that long, it’s simply impossible to know what its long-term effects will be. Thus, it’s impossible to be sure that the long-term effects of vaping will be less severe than those of smoking. Nonetheless, passion to eliminate smoking has promoted this transition away from the devil we know toward a devil we don’t yet understand.
Pages: 1 2 3 | Single Page
3 Responses to “What You Need to Know About Vaping-Associated Pulmonary Injury”
October 22, 2019
David KnoxSeveral points in the article need more clarification. It is not the nicotine or THC that is causing VAPI. People have been inhaling those substances for years without this type of pulmonary inflammatory disease. The carrier oils, or other additives, or their heat generated byproducts are the culprits. The statistics show that 84% of cases have vaped THC containing products and 16% Nicotine only products. Cannabis differs from nicotine as it is not water soluble, and extracts are very viscous, therefore requiring a cutting oil to make it flow in the cartridge in order to evenly contact the heating element. Vitamin E acetate only started to be used as a cutting oil in 2018, so it is a prime suspect in this recent epidemic, but unfortunately does not account for all of the cases of VAPI. The other confounder is related to the legal status of cannabis in this country. In many cases, the vape products were purchased off the street, where there is no oversight as to the contents; counterfeit cartridges abound with who knows what in the mix. Alternatively, there is little incentive to purchase nicotine products on the black market.
Politicians have used this epidemic as a reason to ban flavorings from vaping products, not because they are necessarily the causative agent, but because it ties in to the concern of the appeal of vaping to adolescents, it serves as a tool to address that issue. Banning flavorings may not reduce the incidence of VAPI, other than by possibly reducing the overall number of vapers.
A recent study showed that vaping solutions with NO THC or Nicotine, only the common carrier oils, resulted in inflammation in the lungs of otherwise healthy persons who never vaped or smoked previously. Vaping these products, at temperatures below combustion, still generates many byproducts, including formaldehyde, acetaldehyde, acrolein, etc. Also, these oils vaporize with heat but they condense at body temperature, and precipitate in the airways. This is why tissues show macrophages in the lungs with vacuoles full of oil, but it is not clear that this accounts for the severe inflammatory reaction in VAPI. I would be more suspicious of a heat generated byproduct for some of these cases that do not conform to a diagnosis of lipoid pneumonia.
In absolute numbers, there are only a few thousand cases of VAPI amongst millions of vapers, making the cause even harder to find. This could be from a contaminant or additive, or may depend on any individuals inflammatory reaction to a substance that a majority of vapers tolerate.
To be clear, THC and Nicotine are the reasons WHY people are vaping, but they are NOT the cause of VAPI. It is hard to know if a product is adulterated in the current marketplace, but THC products off the street should certainly be suspect. I applaud the quick research being done on this problem, which hopefully will find a real solution soon. In the meantime, I will continue to advise patients that the long term, or even short term, consequences of vaping are unknown (but may be significant if YOU are the statistic), and this risk needs to be considered strongly in what or how they are using these products.
November 16, 2019
Erica RemerProviders need to be aware that VAPI is not the term that CDC has adopted. They are using, “EVALI,” which stands for “electronic cigarette/vaping associated lung illness.” A new ICD-10-CM code will be created to describe the condition, likely to be presented in March (2020). Providers should probably use the acronym, “EVALI,” instead of VAPI to ensure that the condition is captured accurately by the coders (once the code exists). Would also recommend if your EHR supports acronym expansions, build an Enterprise-wide expansion so there is never any ambiguity.
November 26, 2019
FrankIf you think you might have VAPI and go to the doctor.. what type of tests will they do to determine you have an injury?